Siltuximab

司妥昔单抗

Report date: 2025/06/16 16:57:51
First In Class

Base Information

Drug NameSiltuximab
Drug Alias NameSiltuximabumSylvantcCLB-8CNTO-328
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionInterleukin-6 inhibitors
TargetsInterleukin-6
Therapy Area/IndicationsRejection of lung transplantationMulticentric Castleman's Disease (MCD)Schizophrenia +[32] 
Global Approved IndicationsMulticentric Castleman's Disease (MCD)
Approved Indications in ChinaMulticentric Castleman's Disease (MCD)
Original Approved Country/TerritoryUnited States
Original Approved Date2014/04/23
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesRecordati Netherlands BVInstitute Of Hematology & Blood Diseases HospitalWashington University School Of Medicine +[9] 
Inactive CompaniesJanssen Services LlcXian Janssen Pharmaceutical LtdCilag Ltd +[12] 
Active IndicationsRejection of lung transplantationMulticentric Castleman's Disease (MCD)Schizophrenia +[10] 
Inactive IndicationsDiabetes Mellitus, Type 1Castleman DiseasePrimary Myelofibrosis +[22] 

Other Information

ATC CodeL04AC11
Related LinksWikipediaDrugBankKEGG